HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Patrick M. McCarthy Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massiello, A. Articles by McCarthy, P. M. Search for Related Content PubMed PubMed Citation Articles by Massiello, A. Articles by McCarthy, P. M.

J Thorac Cardiovasc Surg 1994;108:412-419
© 1994 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

The Cleveland Clinic–Nimbus total artificial heart: Design and in vitro function

Cleveland, Ohio, and Rancho Cordova, Calif.

Supported by the National Institutes of Health contract N01-HV-88103.

Received for publication Aug. 4, 1993. Accepted for publication March 16, 1994. Address for reprints: Patrick M. McCarthy, MD, The Cleveland Clinic Foundation, Department of Thoracic and Cardiovascular Surgery, 9500 Euclid Ave., Cleveland, OH 44195.

Abstract

We describe the design and in vitro testing of the Cleveland Clinic-Nimbus electrohydraulic permanent total artificial heart as it nears completion of development. The total artificial heart uses an electric motor and hydraulic actuator to drive two diaphragm-type blood pumps. The interventricular space contains the pump control electronics and is vented to an air-filled compliance chamber. Pericardial tissue valves and biolized blood-contacting surfaces potentially eliminate the need for anticoagulation. In vitro studies on a mock circulatory circuit demonstrated preload-sensitive control of pump output over the operating range of the blood pump: 70 to 160 beats/min and 5 to 9.6 L/min at right and left atrial pressures of 1.0 to 7.0 mm Hg and 5.0 to 12.0 mm Hg, respectively. The pump output was found to be insensitive to afterload over a range of 15 to 40 mm Hg mean pulmonary artery pressure and 60 to 130 mm Hg mean systemic pressure. The left master alternate control mode balanced the ventricular outputs during simulated bronchial artery shunting of up to 20% of cardiac output. A 10% to 15% right-pump, stroke-volume limiter balanced ventricular outputs during maximum output of 9.6 L/min. In response to a sustained increase in systemic venous return, the pump increased output by 2 L/min (29%) in 35 seconds. Thus the Cleveland Clinic–Nimbus total artificial heart meets the National Heart, Lung, and Blood Institute hemodynamic performance goals for devices being developed for permanent heart replacement. The biolized blood-contacting surfaces should decrease the risk of thromboembolism associated with circulatory assist devices. (J THORAC CARDIOVASC SURG 1994;108:412-9)

This article has been cited by other articles:

				W. S. Pierce, J. S. Sapirstein, and W. E. Pae Jr Total Artificial Heart: From Bridge to Transplantation to Permanent Use Ann. Thorac. Surg., January 1, 1996; 61(1): 342 - 346. [Abstract] [Full Text]

				P. M. McCarthy, K. Fukamachi, F. Fukumura, K. Muramoto, L. A. R. Golding, and H. Harasaki The Cleveland Clinic-Nimbus total artificial heart: In vivo hemodynamic performance in calves and preclinical studies J. Thorac. Cardiovasc. Surg., September 1, 1994; 108(3): 420 - 428. [Abstract] [Full Text]